TrialThe oncologist2022
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.
Shumin Yuan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papertrialcites it
TrialThe oncologist2022
Shumin Yuan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.